The United Kingdom and the United States have agreed to a important bilateral deal that will maintain no duties on British pharmaceutical products being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to increase expenditure on pharmaceuticals through the public health system. This move ensures that import taxes on these key goods will remain at zero for a duration of 36 months.
This agreement is in response to previous threats to significantly raise tariffs on branded drug imports, with figures floated as high as double the cost.
"This deal between the United Kingdom reinforces the worldwide climate for new treatments and introduces long-overdue fairness to U.S.–U.K. pharmaceutical trade," an announcement said.
Economic Importance
Pharmaceuticals are one of the Britain's biggest goods shipped to the America, which is clearly the primary buyer for leading UK drugmakers.
Statistics reveal that in the one-year period to the end of September, the UK shipped pharmaceutical products valued at billions to the US. This figure represented 17.4% of British export trade in that span.
"This agreement safeguards employment, boosts investment and sets the stage for the UK to become a international leader for biotech and pharma," the Business and Trade Secretary commented.
Detailed NHS Changes
The deal entails several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to double total NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount drug companies must return to the NHS to control costs will be limited at 15%. In the past, refunds topped 20%.
Broader Context
This agreement follows a ongoing dispute between the sector and the ministers over medicine costs and regulatory access.
This friction were exacerbated by assertions that American consumers were charged several times more for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been halted or scrapped, while major funding commitments have been directed toward projects in the United States.
A senior figure stated that the NHS must spend more on treatments, noting that its spending on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
